Introduction: The aim of this study was to maximise the benefits from clinical trials involving technological interventions such as radiation therapy. High compliance to the quality assurance protocols is crucial. We assessed whether the quality of radiation therapy intervention was evaluated in Cochrane systematic reviews. Methods: We searched 416 published Cochrane systematic reviews and identified 67 Cochrane systematic reviews that investigated radiation therapy or radiotherapy as an intervention. For each systematic review, either quality assurance or quality control for the intervention was identified by a description of such processes in the published systematic reviews. Results: Of the 67 Cochrane systematic reviews studied, only two mentioned quality assurance or quality control. Conclusions: Our findings revealed that 65 of 67 (97%) Cochrane systematic reviews of radiation therapy interventions failed to consider the quality of the intervention. We suggest that advice about the evaluation of intervention quality be added to author support materials.
Introduction
Radiation treatment is an essential component of cancer care. However, radiation treatment is subject to variations in dose, methods and delivery. Delivery of poor quality radiotherapy (RT) that is not compliant with study protocol is associated with diminished efficacy.
1,2 Careful compliance to radiation protocols is thought to be important in achieving the maximum benefit of radiation treatment. Reviews of randomised controlled trials of radiation treatment have indicated that quality assurance (QA) protocols are not commonly utilised. 3 There is also evidence that even when there is a QA protocol stipulated in a trial, radiation protocol deviations are common (11.8-48 .0%). 4 Protocol deviations (the use of poor quality RT) have a significant impact on patient outcomes. 3, 4 Systematic reviews and meta-analyses of randomised controlled trials with homogeneity are viewed as the highest quality evidence for guiding practice in medical care and graded as level of evidence 1a. 5 The Cochrane library is a database of high quality systematic reviews and meta-analyses and is a tool often used to guide practice. However, without appropriate measure of the quality of the delivered intervention, the results of systematic review and meta-analysis may be misleading.
In this review, our objective is to evaluate the assessment of the quality of interventions (radiation therapy or radiotherapy) in the CSRs.
Methods
We searched the Cochrane Library (Issue 12, year 2014) using the keywords 'radiation therapy' or 'radiotherapy' for completed Cochrane systematic reviews (CSRs). We excluded Titles and Protocols. The identified CSRs were examined to determine whether they evaluated RT interventions. We excluded any CSR that did not evaluate an RT intervention (Fig. 1) .
We assessed whether the CSRs mentioned assessment of the quality of the intervention in the description of included studies and the Table of characteristics of included studies. We searched for the following keywords in the identified reviews: quality assurance and quality control. CSRs were considered to have included a QA assessment if any of the keywords was identified. In CSR with assessment of RT quality, we subsequently collected data on the methods used to do so. We searched reference lists of all of the identified CSRs which evaluated RT interventions and then identified references referring to the QA of the RT.
We recorded any descriptions of compliance with RT protocols in the reviews.
We pre-specified these QA measures:
1 Benchmarking; defined as processes aimed at assessing technical aspects of RT, e.g. dosimetry checks using a standardised 'phantom'. 2 Dummy run: where some form of evaluation was used to ensure the staff at the participating institution could show their capacity to meet the protocol requirements. This could include the participating Radiation Oncologist voluming a 'standard' patient, with central review of the radiation treatment volumes to ensure protocol compliance. 3 Centralised QA. This could include: a Prospective QA (generally done by study coordinators): where there was central review of treatment volumes (correlated with the radiological imaging) with feedback, allowing plan improvement. We defined prospective QA ('real-time') as that which is completed before the patient has more than five fractions of RT (before the patient starts the second week of treatment). 'Real-time' QA has the advantage that findings can be fed back to the personnel treating the patients and any problems can be rectified, thus resulting in a QA compliant plan. b Retrospective QA: defined as post-hoc review of RT plans and volumes.
Results
We found 72 CSRs in the Cochrane Library (Issue 12, year 2014). We found two CSRs of RT interventions which included some form of evaluation or itemisation of the QA processes applied to the RT delivered, i.e., an assessment of the quality of the intervention.
The results are summarised in the following Tables 1  and 2 .
The first review identified was by Daly et al. 6 We found two references in the reference lists of this systematic review the describing QA processes utilised. In the SWOG trial as defined in the study protocols, the QA for the interventional arm involved a central review of the completed RT dosimetry by the Radiologic Physics Centre (RPC) and the overall adherence to the protocol by the RT study coordinator. 9 In order to verify that all patients were treated as per protocol, all flow sheets, RT forms, operative and pathology institutional reports, completed daily dose and dosimetry records, films documenting any changes and additional simulation, portal films and Polaroid pictures documenting changes in the treatment field were required to submitted. 9 In the EORTC 22911, as part of the QA, dummy runs were performed at all twelve participating centres. The protocol guidelines, patient inclusion and exclusion criteria, simulation positioning, total dose/fractionation, target volumes definition, techniques, beams arrangements, modifiers shielding of organs at risk (OARs) were defined by the trial centre. 10 This trial discovered a number of CSRs RT QA minor deviations from protocol-total dose (one), fractionation (one), OAR shielding (two), volume reduction for boost volume (two) and dose prescription point. 10 However, it was concluded that none of these deviations affected the outcome of the study. 10 Overall, Daly et al. 6 argued that clear description of treatment volumes, RT techniques, dose prescription and QA were the important measures for any RT trials to show favourable outcomes for RT. The second systematic review that addressed the assessment of QA in RT in clinical trials was authored by O'Rourke et al.
11
, and entitled 'Concurrent Chemoradiotherapy in Non-Small Cell Lung Cancer'. The authors reported that no formal RT QA was performed in the trials.
A subsequent review of all of the reference lists of the CSR's with RT as an intervention found a further three reviews which included references relating to quality. No review had a reference relating to the quality of RT; however, two referenced articles related to surgical quality, and one referenced an article related to pathological quality.
Discussion

Radiotherapy
(alone or with chemotherapy or brachytherapy) is the treatment of choice for 48.3% of notifiable cancers. 12 Delivery of high quality RT is a technically demanding and complex process. Because delivery of RT requires robust QA as an integral part of the process, it is an intervention particularly amenable to the application of clinical trial QA. Careful compliance with RT protocols is important to derive maximum benefit from the treatment. A RT plan, despite its sophistication, will be ineffective if it does not accurately target the tumour. Poor quality RT (defined as non-compliant with study protocols) is less effective and can result in detriment to patient outcomes. 1 In head and neck cancer, a noncompliant plan was associated with a detriment to both local control and overall survival, 2 and in a pancreatic cancer study, overall survival correlated with QA success. 1 The magnitude of the effect of poor quality RT (defined as a non-compliant plan which was not corrected) on survival in a chemo-radiation study was larger than the effect size the study was powered to detect. 2 Radiotherapy quality is measurable; one can measure the dose delivered, the accuracy of target delineation and the actual dose received by the target. This can be done in multiple ways. Investigators at a particular study site may be required to both plan and treat a pseudopatient (a so called 'dummy-run') before their site can be approved to enrol patients in a study.
Study coordinators may request RT planning and treatment documentation for all enrolled patients, which will be assessed either:
1 Before the patient is treated ('real-time QA') which allows changes to be made to make a non-compliant plan compliant or 2 At a later stage (after RT has been completed).
Reviews of randomised controlled trials of radiation treatment have indicated that QA protocols are not commonly utilised. 3 Radiation protocol deviations are common (11.8-48.0%) even when a QA protocol is stipulated in a trial. 4 The addition of a robust QA process to a study does increase the complexity, time, and cost associated with conducting the study. The increasing sophistication and complexity of RT interventions makes it likely that robust QA will have more effect on outcomes. Provision of QA for RT studies has become more sophisticated, and the processes refined to ensure the most valuable exercises are undertaken. Web-based central review can achieve rapid and timely QA. 13 There are risks if RT quality is not evaluated in CSRs. Lack of consistency in trial protocol interpretation, treatment planning and RT delivery can reduce the ability of a trial to generate meaningful results.
14 There are risks if RT quality is not evaluated in CSRs of RT interventions: the authors may incorrectly conclude a lack of effect of the RT intervention, when it was in fact effective, but inadequately delivered. Consideration of evaluation of intervention quality can be considered for other types of interventions. Surrogates for surgical quality might include: 30 day mortality; anastomotic leaks for bowel surgery; or provision of specialised training for particular procedures, as has been explored in surgical treatment of rectal cancer with total meso-rectal excision. 15 Current guidance for authors of CSRs is available in the Cochrane and GRADEPRO handbooks. 16 The GRADE-PRO handbook states: 'guideline panellists should consider downgrading if the intervention cannot be implemented with the same rigour or technical sophistication in their setting'. 17 It may be helpful for reviewers if this explanation was expanded to ensure that review authors consider the converse situation of the trial intervention not being implemented with acceptable rigour or technical sophistication within the trial setting. There is currently little guidance in the Cochrane Handbook of Systematic Reviews of Interventions with respect to evaluating the quality of the intervention. See Chapter 4, section 4.5: 'Comments on how the results of the review fit into the context of current practice might be included here'. 18 Within the review guidelines, correct emphasis has been placed on the assessment of the methodological conduct of the trial, including assessment of the risk of bias; however, there is little emphasis on the assessment of the quality of the actual intervention. We would suggest that some advice with respect to considering intervention fidelity or the quality of the intervention be included in both the GRADEPRO Handbook as well as the Cochrane Handbook. Without some insight into the quality of the RT delivered in reviews of RT interventions, the final conclusions may be unreliable even when a review is performed consistent with current advice given in the Handbook. This may compromise both the generalizability and applicability of the results.
In conclusion, a very small number of systematic reviews emphasised the importance of QA programs for individual clinical trials, as highlighted through this review. Previously, we learnt that major deviations from the trial protocols may have affected the outcomes from a clinical trial, particularly in those investigating a technical intervention such as RT.
It is of concern that the majority of CSRs with radiation treatment as an intervention do not mention QA. Perhaps more concerning is that few proposed protocols for future CSRs include QA in the methodology, as shown in this review. To ensure the quality of conclusions reached in CSRs, QA of the radiation treatment in the included trials should be considered.
The authors recommend that RT QA be considered as major criteria when designing protocols to review any published clinical trial for future systematic reviews investigating RT. A mechanism to ensure this happens could be accomplished by including some advice to this effect in both the GRADEPRO Handbook and the Cochrane Handbook.
